“This recognition belongs to everyone at GARDP and to the extraordinary network of partners, donors, researchers, trial participants and country teams who made this public-private partnership possible,” said Dr Balasegaram.

TIME highlights GARDP’s central role in advancing zoliflodacin, a first-in-class treatment for uncomplicated urogenital gonorrhoea approved by the US FDA in December 2025.

🔗 GARDP statement: gardp.org/dr-manica-ba...

#GlobalHealth #AntimicrobialResistance

This recognition reflects years of collective work at GARDP to develop new antibiotics through a not-for-profit model focused on equitable access.

🚩 A strong close to ACC2026

Panelists underscored the need for better tools, better data and better systems — from WHO-led frameworks to the AWaRe classification to digital visibility across antibiotic use.

💥🔴 This hit home

Dr Manica Balasegaram connects the dots between missing evidence and weak stewardship, reminding us that access without data can quickly undermine innovation.

🔗Head to the discussion now: bit.ly/3LVHIkF

#ACC2026

💊When antibiotics are named generically, misuse follows.

Dr Jeffrey Smith explains how poorly performing, fragmented access systems and generic antibiotic guidance can lead to inappropriate use and lost impact.

🔗The session is still LIVE: bit.ly/3LVHIkF

#ACC2026

🌍🔬 From the closing panel

Access without stewardship risks losing new antibiotics fast. Dr Anita Kotwani points to practical global frameworks that help strengthen antibiotic use and stewardship in primary care settings, particularly in LMICs.

🎥 Join live now: bit.ly/3LVHIkF

#ACC2026

🎯The key takeaway:

“Antibiotics don’t see age, but prescribers do.”

Prof Julia Bielicki drives home why neonates and children are not small adults, and why tiny doses carry big stakes for safety, efficacy and long-term outcomes.

👀Watch the final session of #ACC2026: bit.ly/3LVHIkF

🔴💥 Session Seven moment

“From erections to resurrection — not womb to tomb.”

With that striking opening, Dr Teodora Elvira C. Wi reframes the conversation on STIs, maternal infections and neonatal sepsis, and why early action matters.

🎦Watch the rest of the session LIVE: bit.ly/3LVHIkF

#ACC2026

Dr Sumati Nambiar explains why pregnant women must be ethically and safely included in antimicrobial clinical trials — and why the current evidence gap puts both mothers and babies at risk.

🔗 bit.ly/3LVHIkF

#ACC2026

⚡That’s a wrap on Session Six

A strong finish with new data on fungal colonisation in critical care, followed by an active and thoughtful Q&A with the audience.

⏳ Break time now — but don’t go far. We’re back LIVE soon with Session Seven: From womb to world.

🔗 bit.ly/4rayyzO

#ACC2026

We’ve just heard rapid-fire insights on S. aureus persistence and new strategies against Gram-negative pathogens — and one final oral poster is coming up next.

👀 See it live: portalapp.bsac.eventsair.com/VirtualAtten...

#ACC2026

⭐Session Six highlights

Oral posters opened with data on AMR-related illness and death in advanced HIV, and co-resistance trends in uropathogenic E. coli and Klebsiella

🎥Three more posters to go, watch them live: portalapp.bsac.eventsair.com/VirtualAtten...

#ACC2026

🔚✨ Session Five has just concluded at #ACC2026

Thank you to the speakers for an engaging discussion on the clinical development and use of new agents.

Up next: Session Six – Oral poster presentations, starting shortly.

🔗Join the new session: portalapp.bsac.eventsair.com/VirtualAtten...

Dr Jeremy Dennison dives into the clinical development of GSK's gepotidacin, a novel oral antibiotic targeting uncomplicated UTI, sharing rich detail on its mechanism, data and potential role in care.

It's an energizing one!

🎥 Catch it live: portalapp.bsac.eventsair.com/VirtualAtten...

#ACC2026